SEC Form 4 · accession 0000886163-16-000217
LIGAND PHARMACEUTICALS INC · LGND
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
A later amendment supersedes this filing — read the amendment. The figures below are kept as originally reported (version chain, not an overwrite).
Reporting owner
John W Kozarich
Director
Period of report
Sep 1, 2016
Accepted (ET)
Sep 6, 2016 · 6:07 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000886163
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Sep 1, 2016 | S | 200 | $103.59 | D | 40,783 | D | |
| Common StockF1,F3 | Sep 1, 2016 | S | 400 | $104.6575 | D | 40,383 | D | |
| Common StockF1,F4 | Sep 1, 2016 | S | 866 | $105.8231 | D | 39,517 | D | |
| Common StockF1,F5 | Sep 1, 2016 | S | 200 | $106.865 | D | 39,317 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on December 01, 2015, in accordance with Rule 10b5-1.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $103.22 to $103.96, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $104.29 to $105.17, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F4The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $105.41 to $106.37, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F5The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $106.85 to $106.88, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.